STOCK TITAN

Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 24th Annual Hybrid Global Investment Conference on September 14, 2022, at 12:00 PM (ET). CEO Corey Fishman and CFO Judy Matthews will present a company overview and business update. Investor meetings are scheduled for September 13-14, 2022. The presentation will be accessible for 90 days on the company's website under the 'Investors' section. Iterum focuses on developing innovative antibiotics like sulopenem, which is in Phase 3 clinical development.

Positive
  • None.
Negative
  • None.

DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pm(ET) on Wednesday, September 14, 2022. Management will also host investor meetings on September 13-14, 2022.

Following the conference, a webcast of the presentation will be available to view for 90 days by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.iterumtx.com.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com


FAQ

What will Iterum Therapeutics present at the H.C. Wainwright Conference?

Iterum Therapeutics will provide a company overview and business update at the conference on September 14, 2022.

When are the investor meetings for Iterum Therapeutics?

Investor meetings for Iterum Therapeutics are scheduled for September 13-14, 2022.

How long will the webcast of Iterum Therapeutics' presentation be available?

The webcast will be available for 90 days after the presentation.

What is Iterum Therapeutics developing?

Iterum Therapeutics is developing next-generation oral and IV antibiotics to address multi-drug resistant pathogens.

What is sulopenem and its stage of development?

Sulopenem is Iterum's first compound, currently in Phase 3 clinical development for treating infections.

Iterum Therapeutics plc Ordinary Share

NASDAQ:ITRM

ITRM Rankings

ITRM Latest News

ITRM Stock Data

49.12M
27.10M
1.81%
8.99%
11.15%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2